| Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play W Zhang, P Gou, JM Dupret, C Chomienne, F Rodrigues-Lima Translational oncology 14 (10), 101169, 2021 | 71 | 2021 |
| Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model W Zhang, Y Pan, P Gou, C Zhou, L Ma, Q Liu, Y Du, J Yang, Q Wang Oncology reports 39 (1), 280-288, 2018 | 53 | 2018 |
| Insights into the potential mechanisms of JAK2V617F somatic mutation contributing distinct phenotypes in myeloproliferative neoplasms P Gou, W Zhang, S Giraudier International Journal of Molecular Sciences 23 (3), 1013, 2022 | 15 | 2022 |
| Human CREBBP acetyltransferase is impaired by etoposide quinone, an oxidative and leukemogenic metabolite of the anticancer drug etoposide through modification of redox … W Zhang, J Berthelet, C Michail, LC Bui, P Gou, R Liu, R Duval, J Renault, ... Free Radical Biology and Medicine 162, 27-37, 2021 | 11 | 2021 |
| Tet1-mediated DNA demethylation involves in neuron damage induced by bilirubin in vitro P Gou, X Qi, R Yuan, H Li, X Gao, J Wang, B Zhang Toxicology mechanisms and methods 28 (1), 55-61, 2018 | 10 | 2018 |
| Influence of hypothyroidism on oxidative stress, c-Fos expression, cell cycle, and apoptosis in rats testes JL Wang, HJ Zhang, HL Wang, JW Wang, PH Gou, ZH Ye, YL Wang Toxicological & Environmental Chemistry 97 (10), 1394-1407, 2015 | 10 | 2015 |
| BCL-2 inhibitor venetoclax (ABT-199) and MEK inhibitor GDC-0973 synergise to target AML progenitors and overcome drug resistance with the use of PET scanning in a mouse model … RA Padua, L Sarda-Mantel, M Chiquet, C Kappel, P Krief, N Setterblad, ... Blood 132, 5497, 2018 | 7 | 2018 |
| JAK inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms N Maslah, B Roux, N Kaci, E Verger, R Daltro De Oliveira, H Pasquer, ... Blood 140 (Supplement 1), 795-796, 2022 | 6 | 2022 |
| SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions Q Deng, P Lakra, P Gou, H Yang, C Meydan, M Teater, C Chin, W Zhang, ... Cancer cell 42 (4), 605-622. e11, 2024 | 5 | 2024 |
| Multistage hematopoietic stem cell regulation in the mouse: A combined biological and mathematical approach C Bonnet, P Gou, S Girel, V Bansaye, C Lacout, K Bailly, MH Schlagetter, ... Iscience 24 (12), 2021 | 5 | 2021 |
| A pilot study comparing T-regulatory cell function among healthy children in different areas of Gansu, China P Gou, X Chang, Z Ye, Y Yao, PK Nguyen, SK Hammond, J Wang, S Liu Environmental Science and Pollution Research 24, 22579-22586, 2017 | 5 | 2017 |
| Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms P Gou, D Liu, S Ganesan, E Lauret, N Maslah, V Parietti, W Zhang, ... Blood Cancer Journal 14 (1), 1, 2024 | 3 | 2024 |
| Cisplatin causes covalent inhibition of protein-tyrosine phosphatase 1B (PTP1B) through reaction with its active site cysteine: Molecular, cellular and in vivo mice studies R Liu, W Zhang, P Gou, J Berthelet, Q Nian, G Chevreux, V Legros, ... Biomedicine & Pharmacotherapy 153, 113372, 2022 | 3 | 2022 |
| Modeling the behavior of hematopoietic compartments from stem to red cells in murine steady state and stress hematopoiesis C Bonnet, P Gou, V Bensaye, C Lacout, K Bailly, M Schlagetter, E Lauret, ... Blood 134, 2224, 2019 | 3 | 2019 |
| Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment P Gou, W Zhang Biomedicine & Pharmacotherapy 171, 116130, 2024 | 2 | 2024 |
| Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction S Ganesan, S Awan-Toor, F Guidez, N Maslah, C Aoun, P Gou, ... Blood 140 (Supplement 1), 3852-3854, 2022 | | 2022 |
| Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma Q Deng, C Meydan, P Lakra, D Barisic, CR Chin, E Rojas-Neira, ... Blood 140 (Supplement 1), 1690-1691, 2022 | | 2022 |
| S193: GENOMIC AND FUNCTIONAL IMPACT OF TP53 INACTIVATION IN JAK2V617F MYELOPROLIFERATIVE NEOPLASMS: A TRANSGENIC MOUSE MODEL APPROACH. P GOU, D LIU, E Lauret, N Maslah, V Montcuquet, JJ Kiladjian, B Cassinat, ... HemaSphere 6, 94-95, 2022 | | 2022 |
| Mechanisms of clonal selection in myeloproliferative neoplasms (JAK2V617F) subclonal selection and transformation after TP53 inactivation P Gou Université Paris Cité, 2021 | | 2021 |
| Comparison of In vivo [18F] fluoro-desoxyglucose and [18F] fluoro-thymidine Positron Emission Tomography for disease monitoring in a mouse model of higher-risk myelodysplastic … L Sarda-Mantel, P Gou, F Hontonnou, B Hosten, N Vignal, C San, ... Preprints, 2021 | | 2021 |
